Literature DB >> 30067012

N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Zhi-Chen Wu1, Nicholas A Isley1, Dale L Boger1.   

Abstract

A series of vancomycin derivatives alkylated at the N-terminus amine were synthesized, including those that contain quaternary trimethylammonium salts either directly at the terminal amine site or with an intervening three-carbon spacer. The examination of their properties provides important comparisons with a C-terminus trimethylammonium salt modification that we recently found to improve the antimicrobial potency of vancomycin analogues through an added mechanism of action. The N-terminus modifications disclosed herein were well-tolerated, minimally altering model ligand binding affinities (d-Ala-d-Ala) and antimicrobial activity, but did not induce membrane permeabilization that was observed with a similar C-terminus modification. The results indicate that our earlier observations with the C-terminus modification are sensitive to the site as well as structure of the trimethylammonium salt modification and are not simply the result of nonspecific effects derived from introduction of a cationic charge.

Entities:  

Keywords:  glycopeptide antibiotics; membrane permeabilization; site-specific mechanism of action; vancomycin; vancomycin peripheral modification

Mesh:

Substances:

Year:  2018        PMID: 30067012      PMCID: PMC6200594          DOI: 10.1021/acsinfecdis.8b00152

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  46 in total

1.  Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions.

Authors:  Casey C McComas; Brendan M Crowley; Dale L Boger
Journal:  J Am Chem Soc       Date:  2003-08-06       Impact factor: 15.419

Review 2.  Glycopeptide and lipoglycopeptide antibiotics.

Authors:  Dan Kahne; Catherine Leimkuhler; Wei Lu; Christopher Walsh
Journal:  Chem Rev       Date:  2005-02       Impact factor: 60.622

3.  Telavancin.

Authors:  G Ralph Corey; Martin E Stryjewski; Wim Weyenberg; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

4.  The drug-resistant bacteria that pose the greatest health threats.

Authors:  Cassandra Willyard
Journal:  Nature       Date:  2017-02-28       Impact factor: 49.962

Review 5.  Vancomycin resistance in enterococci: reprogramming of the D-ala-D-Ala ligases in bacterial peptidoglycan biosynthesis.

Authors:  V L Healy; I A Lessard; D I Roper; J R Knox; C T Walsh
Journal:  Chem Biol       Date:  2000-05

6.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

Review 7.  Vancomycin assembly: nature's way.

Authors:  Brian K Hubbard; Christopher T Walsh
Journal:  Angew Chem Int Ed Engl       Date:  2003-02-17       Impact factor: 15.336

8.  Synthesis and biological activity of derivatives of glycopeptide antibiotics eremomycin and vancomycin nitrosated, acylated or carbamoylated at the N-terminal.

Authors:  A Y Pavlov; T F Berdnikova; E N Olsufyeva; E I Lazhko; I V Malkova; M N Preobrazhenskaya; R T Testa; P J Petersen
Journal:  J Antibiot (Tokyo)       Date:  1993-11       Impact factor: 2.649

9.  Synthesis and evaluation of vancomycin aglycon analogues that bear modifications in the N-terminal D-leucyl amino acid.

Authors:  Christine M Crane; Dale L Boger
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 10.  Dalbavancin.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more
  9 in total

1.  Vancomycin C-Terminus Guanidine Modifications and Further Insights into an Added Mechanism of Action Imparted by a Peripheral Structural Modification.

Authors:  Zhi-Chen Wu; Michael D Cameron; Dale L Boger
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

Review 2.  Instructive Advances in Chemical Microbiology Inspired by Nature's Diverse Inventory of Molecules.

Authors:  Ke Liu; Robert W Huigens
Journal:  ACS Infect Dis       Date:  2020-01-06       Impact factor: 5.084

3.  Attenuating the Selection of Vancomycin Resistance Among Enterococci through the Development of Peptide-Based Vancomycin Antagonists.

Authors:  Ryan W Mull; Alec A Brennan; Brittany R Russ; Yftah Tal-Gan
Journal:  ACS Infect Dis       Date:  2020-10-01       Impact factor: 5.084

4.  Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Acc Chem Res       Date:  2020-11-02       Impact factor: 22.384

5.  Exploration of the site-specific nature and generalizability of a trimethylammonium salt modification on vancomycin: A-ring derivatives.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Tetrahedron       Date:  2019-02-04       Impact factor: 2.457

6.  Thiol- and Disulfide-Containing Vancomycin Derivatives Against Bacterial Resistance and Biofilm Formation.

Authors:  Inga S Shchelik; Karl Gademann
Journal:  ACS Med Chem Lett       Date:  2021-10-18       Impact factor: 4.345

7.  More QACs, more questions: Recent advances in structure activity relationships and hurdles in understanding resistance mechanisms.

Authors:  Kelly R Morrison; Ryan A Allen; Kevin P C Minbiole; William M Wuest
Journal:  Tetrahedron Lett       Date:  2019-07-26       Impact factor: 2.415

8.  C1-CBP-vancomycin: Impact of a Vancomycin C-Terminus Trimethylammonium Cation on Pharmacological Properties and Insights into Its Newly Introduced Mechanism of Action.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Akinori Okano; William J Weiss; Dale L Boger
Journal:  J Org Chem       Date:  2019-10-31       Impact factor: 4.354

Review 9.  Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

Authors:  Emma van Groesen; Paolo Innocenti; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-07-27       Impact factor: 5.578

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.